Understanding Hormonal Acne and the use of Spironolactone

Acne vulgaris is a complex, multifactorial skin disorder—driven by increased sebum production, follicular hyper-keratinisation, proliferation of Cutibacterium acnes, and inflammation. But for many women, there is a significant hormonal component.Hormonal acne typically presents differently from classic adolescent acne: it often occurs across the lower face, jaw-line, chin and neck; flares cyclically (e.g., around the pre-menstrual period); may feature deeper nodules or cysts; and may persist into the third or fourth decade of life.In these cases, androgens (male hormones present in all women) or increased sensitivity of the sebaceous follicles to androgens can play a key role. Conditions such as Polycystic Ovary Syndrome (PCOS) or other endocrine dysregulation can exacerbate this picture. Management of hormonal acne therefore requires not only conventional treatments (topical retinoids, benzoyl peroxide, systemic antibiotics, isotretinoin) but also attention to the hormonal drivers. For women in whom acne is persistent, recurrent or shows a clear hormonal pattern (jaw-line distribution, associated hirsutism, menstrual irregularities), treatments that target the androgen axis are increasingly considered.

Conventional Treatment of Hormonal Acne

First-line management of acne in women remains the standard dermatology approach: topicals (retinoids, benzoyl peroxide, azelaic acid), appropriate lifestyle advice (skin care, non-comedogenic products, diet, sleep), and oral treatments (e.g., antibiotics for moderate inflammatory acne). Hormonal treatments (for example combined oral contraceptive pills or anti-androgens such as cyproterone acetate) are often added in women with suspected endocrine influence.However, for many women the acne remains refractory despite multiple lines of therapy, or they cannot tolerate long-term antibiotics (especially given concerns about antimicrobial resistance) or isotretinoin. In such cases, alternative systemic options that address hormonal pathways merit consideration.

Spironolactone and Female Hormonal Acne

Spironolactone is a well-known medication in cardiology and nephrology — primarily as a potassium-sparing diuretic/aldosterone antagonist — but dermatologists have increasingly used it “off-licence” for female hormonal acne. According to the British Association of Dermatologists (BAD), spironolactone is indeed utilised off-licence to treat women with acne and features of androgen-driven skin disorders.

In the UK, while spironolactone is not formally licensed for acne (i.e., the Summary of Product Characteristics does not specify acne as an approved indication), recent guidance in Scotland and elsewhere recognises its role in “persistent acne in adult females” unresponsive to standard therapy, providing practical guidance to prescribers.

One major recent trial — the SAFA study (Spironolactone for Acne in Females) — demonstrated that spironolactone was significantly more effective than placebo in women with persistent acne, with up to 72 % self-assessed improvement at 12 weeks and 82 % by 24 weeks.

So, while strictly not “licensed” for acne in the UK, the evidence base is growing and dermatology clinics (including online services) are increasingly offering it—provided proper assessment and monitoring is in place.

How Spironolactone Works

Spironolactone’s beneficial effect in hormonal acne is principally mediated through its anti-androgenic properties:

• It may reduce circulating free androgen levels and diminish downstream androgen-driven sebum output, helping to reduce greasiness, clogged follicles, comedones, inflammatory nodules and cysts.

• Because it addresses one of the underlying hormonal triggers rather than simply suppressing the bacteria or inflammation, it can be particularly useful in the “jaw-line, cyclic, hormonally driven” phenotype of acne that many women present with.

• 
  

Practical Use, Dosing and Time-Course

In clinical practice in the UK:

• It should be emphasised that improvement is gradual — many women see initial signs of improvement around 3 months, but full effect may require 6 months or longer.

• Treatment may need to continue for as long as the acne remains active; stopping too early may lead to recurrence. Some women remain on the drug for 1–2 years or longer if effective.

• Spironolactone is often used in conjunction with topical therapies and sometimes hormonal contraceptives (which also help reduce androgen effects), rather than as a sole agent.

  
  

Side-Effects and Monitoring

Despite its favourable profile for many women, spironolactone is not without risks and appropriate monitoring is essential.

Common side-effects include:

• Menstrual irregularities (spotting, heavier flows, less frequent periods) and sometimes amenorrhoea.

• Breast tenderness or breast enlargement.

• Increased urinary frequency or diuresis.

• Dizziness or postural hypotension (especially early after starting or increasing dose).

  
  

  Less common/important considerations:

• Hyperkalaemia (raised potassium) — especially in older women (>45 yrs), those with renal/cardiac disease, or on other potassium-sparing or ACE-inhibitor drugs. Baseline renal function/U&E and potassium should be checked.

• Potential teratogenic effect in male foetus (feminisation) — contraceptive advice is essential and spironolactone is contraindicated in pregnancy.

• Because the use is off-licence for acne, clear informed consent and counselling about risks/benefits is required.

  
  

  Monitoring recommendations:

• Pre-treatment: check U&E, blood pressure, ensure potassium < 5 mmol/L, assess renal/cardiac status.

• In younger healthy women (<45, no renal/cardiac disease) ongoing monitoring may be minimal (e.g., annually). For older women or those with comorbidities, more frequent monitoring (1 wk, then monthly, then quarterly) may be advised.

• Encourage low-potassium diet (avoid salt substitutes high in K+, reduce high-potassium foods) when relevant.

  
  

How mySkinDoc Can Help

At mySkinDoc, as an online UK dermatology clinic, we specialise in helping patients with hormonal acne through a comprehensive, evidence-based and patient-centred approach. Here’s how we can support you:

1. Detailed remote assessment: We begin with a structured virtual consultation that reviews your acne history (pattern, severity, previous treatments), hormonal symptoms (e.g., menstrual irregularity, hirsutism, hair loss, cyclical flares), lifestyle factors, medications and comorbidities.

2. Investigation and stratification: If hormonal acne is suspected (jaw-line distribution, adult-onset, cyclic flare, signs of androgen excess), we may recommend appropriate baseline tests (e.g., U&E, potassium, renal function, possible endocrine screen) and collaborate with you to decide whether systemic anti-androgen therapy such as spironolactone is a suitable option.

3. Shared decision-making: We’ll explain the benefits, limitations and off-licence status of spironolactone in acne, discuss monitoring requirements, contraceptive implications (if applicable), and help you weigh this against other options (such as oral antibiotics, hormonal contraceptives, isotretinoin).

4. Prescription and monitoring: Once a treatment plan is agreed, we can prescribe spironolactone (if appropriate). We liaise with your GP or local provider if required and provide clear written instructions on lifestyle measures (dietary potassium, fluid intake, contraceptive use).

5. Complementary therapies and follow-up: We combine systemic therapy with optimised topical skincare, non-comedogenic product advice, lifestyle and diet counselling.

6. Support and education: Hormonal acne can be frustrating, cyclical and long-term. We provide patient-friendly education, realistic timelines (improvement often 3–6 months) andmset expectations (not an overnight “cure”).

   
   

Summary

Hormonal acne in women—and particularly adult female acne with jaw-line distribution, cyclical flares or androgen excess features—requires more than standard topical and antibiotic treatments. Spironolactone offers a compelling option: by blocking androgen receptor activity in sebaceous glands it addresses a key driver of hormonal acne. Although its use for acne is off-licence in the UK, the evidence base is growing and current guidance supports its use in adult women with persistent acne unresponsive to first-line therapies. At mySkinDoc we provide the structured assessment, safe prescribing and monitoring framework needed to use spironolactone effectively and safely as part of a modern, patient-centred dermatology service. If you’ve been struggling with hormonal acne and want a tailored plan that goes beyond topical creams, we’d be delighted to help you explore whether spironolactone is the right path forward for you.

This article was written by Dr Goyal, Director at mySkinDoc